Rexulti Class Action | Rochon Genova

Class Members must submit a completed Claim Form to the Administrator no later than August 27, 2026. Claim Forms are available for download on the Settlement Website and below.

Settlement Website

http://www.rexulticlassactionsettlement.com/

The Claims

Rexulti is the trademark for the drug, brexpiprazole. Rexulti was approved as treatment for schizophrenia in Canada in February 2017, and as treatment for depression in February 2019.

This national class action, filed in the Quebec Superior Court of Justice, alleges that Otsuka and Lundbeck – the pharmaceutical companies responsible for developing and marketing Rexulti – failed to provide Canadian uses with adequate and timely warnings about the increased risk of impulse control disorders and compulsive behaviours, such as compulsive gambling, compulsive shopping/spending, hypersexuality and binge-eating.

Rexulti is a partial dopamine agonist that is alleged to be substantially similar to the antipsychotic drug aripiprazole (marketed under the trade names Abilify and Abilify Maintena). Abilify and Abilify Maintena were approved in Canada in 2009 and 2014, and have also been associated with impulse control disorders and compulsive behaviours.

Otsuka developed Abilify and Abilify Maintena and has been commercializing and marketing them in Canada along with Bristol-Myers Squibb Canada Co. and Lundbeck Canada Inc., respectively. The claim alleges that the Otsuka and Lundbeck companies intentionally developed Rexulti to be substantially similar to Abilify, because Abilify was losing patent protection. The similarity in the chemical structures of Rexulti and Abilify/Abilify Maintena was noted in the Health Canada Summary Basis of Decision for Rexulti.

The Class

All persons in Canada who were prescribed and used the prescription antipsychotic drug REXULTI during the Class Period starting from February 16, 2017 and who developed one or more of the following Compulsive Behaviours and Impulse Control Disorders: Compulsive Gambling, Hypersexuality, Binge eating, and Compulsive shopping and/or spending.

Updates

On October 9, 2018, the class action was commenced.
On December 3, 2021, the Quebec Superior Court of Justice certified a national class action on behalf of REXULTI® Class Members relating to the Defendant drug manufacturers’ alleged failure to warn of the risks of compulsive gambling, hypersexuality, compulsive shopping, and binge eating associated with REXULTI®.
Notice of authorization of the Class Action was provided on March 15, 2024. The opt-out deadline for Class Members who did not wish to participate in the Class Action expired on May 15, 2024.
On August 23, 2025, the parties reached a settlement agreement.
On November 13, 2025, the Superior Court of Québec approved the parties settlement agreement.
The Settlement provides for payment of CDN $4.75 million, which will be used to pay compensation for Approved Claims, $118,750.00 in satisfaction of the claims of the Public Health Insurers, the costs of notice and administration, and Court-approved Class Counsel legal fees in the amount of $1,425,000.00, disbursements and taxes. The Court has appointed MNP Ltd. as Administrator of the Settlement.
Settlement Benefits will be distributed in accordance with the Distribution Protocol approved by the Court. Not all Class Members will be eligible for compensation.
On July 27, 2026, the deadline to submit a claim to receive benefits under this Settlement has been extended from July 27, 2026 to August 27, 2026